Saracatinib: all 33 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Saracatinib and Alcohol DrinkingCompletedNCT02955186Phase 2Results posted
• Investigating the Interactions of AZD0530 With Alcohol in Social DrinkersCompletedNCT02732587Phase 1Results posted
• A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's DiseaseCompletedNCT02167256Phase 2Results posted
• Saracatinib in Treating Patients With Prostate CancerTerminatedNCT01267266Phase 2Results posted
• A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast CancerCompletedNCT01216176Phase 1/2Results posted
• Saracatinib and Paclitaxel in Platinum-resistant Ovarian CancerCompletedNCT01196741Phase 2/3Results posted
• A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the LungTerminatedNCT00752206Phase 2Results posted
• Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic CancerCompletedNCT00735917Phase 2Results posted
• Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic CancerTerminatedNCT00718809Phase 2Results posted
• Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00669019Phase 2Results posted
• AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00659360Phase 2Results posted
• AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination ChemotherapyCompletedNCT00638937Phase 2Results posted
• AZD0530 Phase II Study in Patients With Advanced Ovarian CancerCompletedNCT00610714Phase 2Results posted
• Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction CancerCompletedNCT00607594Phase 2Results posted
• Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By SurgeryCompletedNCT00559507Phase 2Results posted
• Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone DiseaseCompletedNCT00558272Phase 2Results posted
• AZD0530 in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00528645Phase 2Results posted
• Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00513435Phase 2Results posted
• AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00513071Phase 2Results posted
• AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal CancerTerminatedNCT00397878Phase 2Results posted
• Saracatinib Trial TO Prevent FOPActive, not recruitingNCT04307953Phase 2
• SRC Inhibition as a Potential Target for Parkinson's Disease PsychosisStatus unknownNCT03661125Early Phase 1
• Safety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisTerminatedNCT02737202Phase 2
• The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of AlcoholismCompletedNCT02262026Phase 1
• The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)CompletedNCT02116712Phase 1
• SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone PainCompletedNCT02085603Phase 2
• Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's DiseaseCompletedNCT01864655Phase 1
• Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and PaclitaxelWithdrawnNCT01000896Phase 1
• Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male VolunteersCompletedNCT00853983Phase 1
• Relative Bioavailability of Phase II and Phase III Formulations of AZD0530CompletedNCT00771979Phase 1
• AZD0530 Study 21 - Phase I Study in Patients With Solid TumoursCompletedNCT00704366Phase 1
• Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursCompletedNCT00475956Phase 1
• AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00265876Phase 1/2

← Saracatinib overview